Eisai executive behind Alzheimer’s therapy Leqembi retires
olm26250

Japanese drugmaker Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced Tuesday that Ivan Cheung, who helped lead the company's development efforts with Biogen (NASDAQ:BIIB) for Alzheimer's therapy Leqembi will retire at the end of this month.
According to his LinkedIn profile, Cheung performed dual roles for Eisai (OTCPK:ESALF) as the global head of the company's neurology business and CEO/ President of its U.S. unit Eisai Inc.

Keisuke Naito, the son of Eisai (OTCPK:ESALF) Chief Executive Haruo Naito, will take over Cheung's leadership position in the company's Alzheimer's portfolio in an acting capacity.
Meanwhile, Chief Financial Officer Tatsuyuki Yasuno will become acting chairman and CEO of Eisai Inc.
The FDA issued full approval for Eisai (OTCPK:ESALF) and Biogen's (BIIB) Alzheimer's therapy Leqembi early this month after granting conditional approval in January.


More on Eisai

Eisai: Looking To Upside Targets Following Leqembi Full Approval
Eisai: Potentially The Best Bet On The Alzheimer's Treatment Market